中国高尿酸血症患者HLA-B58:01基因的人群分布

发布时间：2018-11-14 17:18

【摘要】：目的全面了解中国大陆各地区HLA-B*58:01基因的阳性率和频率,有效地指导高尿酸血症患者临床用药及临床基因筛查的必要性。方法对中华骨髓库891 793例中国大陆人群行HLA高分辨分型,并按31个省市自治区分层,明确HLA-B*58:01基因阳性率和基因频率。结果中国大陆人群HLA-B*58:01基因阳性率呈现南方人群中较其他地区高;按地区分类,华南地区的HLA-B*58:01基因阳性率最高,西南地区及北方地区阳性率较低;按省市自治区分类,阳性率较高的分别为福建(28.43%)、广西(20.75%)、海南(20.20%)、广东(19.66%)、浙江(18.38%),阳性率较低的为天津(3.52%)、内蒙古(3.49%)、西藏(3.27%)、河北(3.11%)、山西(3.08%)。结论重视高尿酸血症HLA-B*58:01基因阳性人群,尤其应对中国南方人群高尿酸血症患者进行HLA-B*58:01基因筛查,以避免使用别嘌呤醇所致严重不良后果。
[Abstract]:Objective to understand the positive rate and frequency of HLA-B*58:01 gene in different regions of mainland China, and to effectively guide clinical drug use and gene screening in patients with hyperuricemia. Methods High-resolution HLA typing was performed in 891,793 Chinese mainland population. The positive rate and frequency of HLA-B*58:01 gene were determined according to 31 provinces and autonomous regions. Results the positive rate of HLA-B*58:01 gene in the population of mainland China was higher than that in other regions, and the positive rate of HLA-B*58:01 gene in South China was the highest, and the positive rate of HLA-B*58:01 gene was lower in the southwest and north of China. The positive rates were higher in Fujian (28.43%), Guangxi (20.75%), Hainan (20.20%), Guangdong (19.66%) and Zhejiang (18.38%), respectively. The positive rates were lower in Tianjin (3.52%), Inner Mongolia (3.49%), Tibet (3.27%), Hebei (3.11%) and Shanxi (3.08%). Conclusion attention should be paid to the HLA-B*58:01 gene positive population with hyperuricemia, especially the patients with hyperuricemia in southern China should be screened for HLA-B*58:01 gene, so as to avoid the serious adverse consequences caused by allopurinol.
【作者单位】：南京医科大学第一附属医院HLA与移植免疫实验中心;北京市红十字血液中心;中华骨髓库质量控制实验室;重庆市血液中心;河北省血液中心;中国医学科学院输血研究所;辽宁省血液中心;山西省太原市红十字中心血站;辽宁省大连市红十字血液中心;中国造血干细胞捐献者资料库管理中心技术服务部;南京医科大学第一附属医院内分泌科;
【基金】：江苏省卫生和计划生育委员会科技项目(Z201401)
【分类号】：R589.7

【相似文献】